Proton pump inhibitors and colorectal cancer:A systematic review

作     者：Agastya Patel Piotr Spychalski Magdalena Antoszewska Jaroslaw Regula Jarek Kobiela 

作者机构：Department of GeneralEndocrine and Transplant SurgeryMedical University of GdanskGdansk 80-210Poland Department of DermatologyVenereology and AllergologyMedical University of GdanskGdansk 80-210Poland Department of GastroenterologyHepatology and OncologyCenter of Postgraduate Medical EducationThe Maria Sklodowska-Curie National Research Institute of OncologyWarsaw 01-813Poland 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2021年第27卷第44期

页      面：7716-7733页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Colorectal cancer Proton pump inhibitor Carcinogenesis Cancer epidemiology Capecitabine Translational medicine 

摘      要：BACKGROUND The use of proton pump inhibitors(PPI)is common worldwide,with reports suggesting that they may be *** studies have found that PPI may affect colorectal cancer(CRC)*** To summarize current knowledge on the relationship between PPI and CRC from basic research,epidemiological and clinical *** This systematic review was based on the patients,interventions,comparisons,outcome models and performed according to PRISMA ***,EMBASE,Scopus,and Web of Science databases were searched from inception until May 17,*** initial search returned 2591 articles,of which,28 studies met the inclusion criteria for this *** studies were categorized as basic research studies(n=12),epidemiological studies(n=11),and CRC treatment studies(n=5).The quality of the included studies was assessed using the Newcastle-Ottawa Scale or Cochrane Risk of Bias 2.0 tool depending on the study *** Data from basic research indicates that PPI do not stimulate CRC development via the trophic effect of gastrin but instead may paradoxically inhibit *** studies also suggest that PPI may have properties beneficial for CRC *** appear to have anti-tumor properties(omeprazole,pantoprazole),and are potential T lymphokine-activated killer cell-originated protein kinase inhibitors(pantoprazole,ilaprazole),and chemosensitizing agents(pantoprazole).However,these mechanisms have not been confirmed in human *** epidemiological studies suggest that there is no causal association between PPI use and increased CRC *** studies show that concomitant PPI and capecitabine use may reduce the efficacy of chemotherapy resulting in poorer oncological outcomes,while also suggesting that pantoprazole may have a chemosensitizing effect with the fluorouracil,leucovorin,oxaliplatin(FOLFOX)*** An unexpected inhibitory effect of PPI on CRC carcinogenesis by way of several potential mechanisms is *** review